Publications by authors named "Yuji Yata"
Objectives: This study explored the impacts of peri-operative changes in the neutrophil-to-lymphocyte ratio (NLR) on the survival rate after radical nephroureterectomy.
Methods: This retrospective analysis included a multicentric cohort of patients diagnosed with upper tract urothelial carcinoma (UTUC) who had undergone radical nephroureterectomy from 2012 to 2021. We assessed the preoperative NLR, postoperative NLR, delta-NLR (difference between postoperative and preoperative NLRs), and NLR change (ratio of postoperative to preoperative NLR).
Article Synopsis
- - A study analyzed the effectiveness of two drugs, enzalutamide and apalutamide, in treating patients with non-metastatic castration-resistant prostate cancer (nmCRPC) to understand their efficacy and adverse event (AE) profiles.
- - The research involved 191 patients, revealing that both drugs led to similar oncological outcomes, with comparable PSA response rates and no significant differences in progression-free survival (PFS) or overall survival (OS).
- - However, the side effects varied, with enzalutamide causing more fatigue and apalutamide leading to more skin rashes, indicating their differential usage may depend on AE profiles despite similar efficacy.
Article Synopsis
- Enfortumab vedotin (EV) is an antibody-drug conjugate used for treating metastatic urothelial carcinoma (UC) in patients who previously underwent immune checkpoint inhibitor (ICI) treatment, specifically avelumab or pembrolizumab.
- A study involving 100 patients revealed that while progression-free survival (PFS) was better for those treated with EV after avelumab, overall survival (OS) rates were not significantly different between the two treatment groups.
- Key prognostic factors affecting outcomes included histological variants, liver metastasis, low serum albumin, and high serum CRP levels, with cachexia patients experiencing particularly poor prognosis.
Article Synopsis
- A systematic review showed that a specific histological variant of upper tract urothelial carcinoma (UTUC) leads to worse outcomes compared to pure UTUC.
- This study examined 824 Japanese patients with UTUC to assess how variant histology impacts disease severity and patient survival after surgery.
- Results indicated that while variant histology was linked to worse recurrence and survival rates, its significance diminished when other factors were considered, suggesting it may not provide additional prognostic value in Japanese patients.
Objective: We aimed to assess the impact of the timing of urinary drainage on clinical outcomes in patients with obstructive pyelonephritis (OPN) associated with upper urinary tract (UUT) stones.
Methods: We retrospectively evaluated the multicenter dataset of 240 patients with OPN associated with UUT stones who underwent urinary drainage. We divided the patients into two groups depending on the timing of urinary drainage; emergency drainage, defined as within 12 h from admission, and delayed drainage, defined as between 12 and 48 h from admission.
Article Synopsis
- There is limited understanding of how to best manage and predict outcomes for patients with node-positive upper tract urothelial carcinoma (UTUC).
- A study analyzed data from 105 patients to determine factors affecting overall survival (OS) after treatments like radical nephroureterectomy (RNU) and chemotherapy.
- Results indicated that patients who received RNU had significantly better OS compared to those who did not, and factors like low G8 score and high pretreatment C-reactive protein (CRP) were linked to worse outcomes.
Objectives: To explore the characteristics of patients and assess the effectiveness of enfortumab vedotin (EV) in those with treatment-resistant advanced urothelial cancer in a real-world setting.
Patients And Methods: A multicenter observational study was conducted on 103 evaluable patients with advanced urothelial cancer who received EV. Outcomes were assessed by radiographic response, progression-free survival (PFS), and overall survival (OS), with treatment-related adverse events (trAEs).
Article Synopsis
- * A study analyzed 895 patients who underwent nephroureterectomy for UTUC, categorizing them into two groups: those eligible for adjuvant immunotherapy and those not eligible, and evaluated their oncological outcomes through statistical models.
- * Findings indicated that the group eligible for adjuvant immunotherapy had poorer recurrence-free, cancer-specific, and overall survival rates, with pathological grades and lymphovascular invasion serving as significant risk factors for survival outcomes.
Article Synopsis
- * Results showed that 37% of patients who had neoadjuvant chemotherapy experienced pathological downstaging, while those receiving adjuvant chemotherapy had significantly lower recurrence-free and cancer-specific survival rates.
- * The findings suggest that neoadjuvant chemotherapy may be a more effective treatment option for high-risk patients compared to adjuvant chemotherapy.
Purpose: We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real-world clinical practice setting.
Methods: The records of 336 patients who harbored de novo high-risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC (n = 109) or ABI (n = 227) were retrospectively analyzed. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), time to 2nd-line progression (PFS2), and 2nd- and 3rd-line PFS, were compared.
While renal cell carcinoma frequently metastasizes to the lung, solitary pleural metastasis without lung involvement is extremely rare. A 69-year-old man was admitted to our hospital with a solitary pleural metastasis 6 years after surgery for renal cell carcinoma. Needle biopsy was performed, and the tumor was diagnosed as a metastasis of renal cell carcinoma.
View Article and Find Full Text PDF